Abstract: A method for treatment and prevention of neonatal hyperbilirubinemia by oral administration of a preparation comprising Castor oil, Honey and Cellulose fibers with other additives.

Abstract: The present invention relates to the new compound rac-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)1,4 -dihydro-2,6-dimethylpyridine-3,5-dicarboxylate and its pure enantiomers, processes for their preparation and their use as medicaments, in particular for the treatment of cerebral and neuronal disorders, and a new intermediate for their preparation.

Abstract: The present invention provides a method for providing nutrition to non-catabolic and moderately catabolic patients. Pursuant to the present invention, the enteral composition includes a peptide based protein source of hydrolyzed whey, a lipid source, and a carbohydrate source. Preferably, the protein source includes approximately 22% to about 27% of the total calories. The composition has a caloric density of approximately 1000 Kcal/L and a low osmolality of approximately 300 to 450 mOsm/Kg H.sub.2 O. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.

Abstract: This invention relates to the use of L-acylcarnitine for the preparation of a drug and a technique for relieving the disease symptoms appearing in AIDS by administering an L-acylcarnitine. The invention furthermore relates to a drug for this purpose, characterized in content by L-acylcarnitine as active principle. The preferred L-acylcarnitine is L-acetylcarnitine.

Abstract: The subject invention relates to desquamation compositions comprising a combination of salicylic acid and certain zwitterionic surfactants. The subject invention further relates to methods of desquamation in mammalian skin and treating acne in mammalian skin.

Abstract: A medical food having the below listed components is administered for several days as the sole source or as a substantial source of the daily caloric intake of a patient suffering from metabolic poisoning: 45 to 65% protein concentrate; 2.5 to 17.5% of grain syrup solids containing 50% dextran; 2.5 to 17.5% of grain syrup solids containing 50% of maltose; 3 to 12% of oil containing 20% of oleic acid, 1 to 11% medium chain triglycerides; magnesium ions; buffering agent; soluble calcium salt; ascorbic acid; 0.40 to 0.65% of .beta. carotene; D-.alpha.-tocopherol; chromium ions in the trivalent or hexavalent form, 0.008 to 0.022% glutathione, 0.08 to 0.22% N-acetylcysteine; L-lysine hydrochloride; 0.08 to 0.22% L-threonine, and 0.08 to 0.22% of L-cysteine.

Abstract: A novel therapeutical utilization of L-carnitine, acyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed, for treating immune and metabolic alterations in patients suffering from AIDS and AIDS-related syndromes and in asymptomatic HIV-seropositive patients.The L-carnitine amount to be administered according to this novel use is about 6-8 grams daily, via the oral route or an equivalent amount of an acyl L-carnitine or a pharmacologically acceptable salt thereof, i.e. three-four times as much the dose usually administered for the already known therapeutic uses of L-carnitine.

Abstract: A medical food having the below listed components is administered for several days as the sole source or as a substantial source of the daily caloric intake of a patient suffering from metabolic poisoning: 45 to 65% protein concentrate; 2.5 to 17.5% of grain syrup solids containing 50% dextran; 2.5 to 17.5% of grain syrup solids containing 50% of maltose; 3 to 12% of oil containing 20% of oleic acid, 1 to 11% medium chain triglycerides; magnesium ions; buffering agent; soluble calcium salt; ascorbic acid; 0.40 to 0.65% of .beta. carotene; D-.alpha.-tocopherol; chromium ions in the trivalent or hexavalent form, 0.008 to 0.022% glutathione, 0.08 to 0.22% N-acetylcysteine; L-lysine hydrochloride; 0.08 to 0.22% L-threonine, and 0.08 to 0.22% of L-cysteine.

Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises a nitrogen-containing compound for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one nitrogen-containing compound for the preparing of an inositol phosphate containing medicament with improved bioavailibility of inositol phosphate in mammals including man at non-parenteral administration.

Abstract: L-carnitine trichloroacetate and its use for producing cosmetic and pharmaceutical compositions suitable to be topically applied for the treatment of dermatoses, are disclosed.

Abstract: The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

Abstract: Obesity is treated by the administration to a subject of a compound having the general formula (I): R.sub.4 --(CH.sub.2).sub.n --CO--N(R.sub.1)--CH(R.sub.2)--CO(--R.sub.3), wherein R.sub.1 represents H or CH.sub.3 ; R.sub.2 represents a side chain of a naturally occurring amino acid; R.sub.3 represents OH, OCH.sub.2 CH.sub.3 and NH.sub.2 ; n is 6-18; and R.sub.4 represents CH.sub.3 or a group having the general formula (II): R.sub.3 --CO--CH(R.sub.2)--N(R.sub.1)--CO--, wherein R.sub.1, R.sub.2 and R.sub.3 have the above meanings. The compounds of formula (I) wherein R.sub.4 is a group of formula (II), are novel compounds.

Abstract: The present invention relates to a method of using a preparation of triacylglycerol which contains unsaturated fatty acids having no more than two double bonds to preserve normal erythrocyte deformability, to improve microcirculation, to protect myocardium against ischemic damage and to suppress arrhythmia in ischemic heart, i.e. to protect cells and tissues of a mammalian body against various forms of mechanical and chemical injuries.

Abstract: A method of treating a patient in need of stimulation of hepatocyte mitosis which comprises administering to said patient an effective amount of alanine and/or glutamine.

Abstract: The present invention relates generally to a generic powder base rich in fats, carbohydrates, vitamins and minerals and trace elements which can be readily admixed with specific amino acids to yield several different therapeutic products for use in the nutritional support of various inherited metabolic diseases.

Abstract: The present invention provides a new therapeutic use of the zwitterionic surfactants, specifically betaines and sulfobetaines, to treat cellular, neoplastic disorders.

Abstract: An active ingredient for a therapeutic or cosmetic composition is obtained from live gastropoda (e.g., snails) which are physically stimulated (e.g., by centrifuging) to cause secretion of a fluid which is then centrifuged and filtered. Preferably the gastropoda are fasted prior to the physical stimulation. The therapeutic or cosmetic compositions contain about 0.1-30% of the active ingredient which is a mixture of amino acids and atoxic substances, an effective amount of an excipient preferred for use with biologically active ingredients, and other conventional ingredients provided they do not affect the stability and/or the activity. The therapeutic composition, in the form of a topical cream, can be used to treat various types of burns, dermatitis, eczema, diaper rash, and difficult to heal wounds. It can also be used to prevent skin cancer and radiodermatitis. The cosmetic composition can be used as hand and face creams, an anti-wrinkle cream, a sunscreen cream, a moisturizing lotion, and a deodorant.

Abstract: Intestional absorption of zwitterionic compounds is enhanced when the compound is delivered with the absorption enhancer palmitoyl carnitine chloride and the solubilizing agent .beta.-cyclodextrin when compared to delivery with palmitoyl carnitine chloride or .beta.-cyclodextrin alone.

Abstract: The invention provides a pharmaceutical composition for treating performance anxiety and social phobia comprising a therapeutic amount for the treatment of a patient of a .beta.-adrenergic receptor blocking compound and an anti-diaphoretic compound. The preferred .beta.-adrenergic receptor blocking compound is the lipophilic .beta.-blocker propranolol HCL. The anti-diaphoretic compound of the present invention is preferably glycopyrrolate. The composition for treating performance anxiety and social phobia can further include a pharmaceutically acceptable carrier. A method of preventing or treating performance anxiety or social phobia in a patient comprising administering the composition of the invention to a patient in need of such treatment is also provided. The composition administered in the present method comprises a therapeutic amount of a .beta.-adrenergic receptor blocking compound and an anti-diaphoretic compound.

Abstract: Hydroxamic acid derivatives of formula (I): ##STR1## wherein R.sup.1 represents hydrogen or an (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxycarbonyl(C.sub.1 -C.sub.6)alkyl, phenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl, phenacyl or substituted phenacyl group;R.sup.2 represents hydrogen or a (C.sub.1 -C.sub.6)alkyl, (C.sub.2 -C.sub.6)alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group,R.sup.3 represents a group --CH.sub.2 CO.sub.2 (C.sub.1 -C.sub.4)alkyl or --CH.sub.2 CH.sub.2 CO.sub.2 (C.sub.1 -C.sub.4)alkyl;R.sup.4 represents hydrogen or a (C.sub.1 -C.sub.6)alkyl or phenyl(C.sub.1 -C.sub.6)alkyl group;R.sup.5 represents hydrogen or a methyl group;n is 0, 1 or 2;and A represents a (C.sub.1 -C.sub.6)hydrocarbon chain optionally substituted with one or more (C.sub.1 -C.sub.

Abstract: Described is a method of treating diarrhea in a warm-blooded vertebrate animal, and a composition therefor. The method involves administering to the animal an effective amount of a methylamine, such as betaine. Also described is the use of a composition for the manufacture of a medicament for treatment of diarrhea in a warm-blooded vertebrate animal, wherein the composition contains an effective amount of a methylamine, such as betaine.

Abstract: Aqueous dispersions of polymers which have a high glass transition temperature and a low average molecular weight and contain a specific amount of methacrylic acid as polymerized units are suitable, in liquid or dried form, as additives for improving the flow behavior of cement-containing mineral building materials having binding properties.

Abstract: The use of O-esters of L-carnitine with saturated bicarboxylic acids (e.g. azelaic, sebacic, suberic and pimelic acid) or unsaturated monocarboxylic acids (e.g. linoleic, linolenic, oleic and orachidonic acid) is disclosed for producing pharmaceutical compositions suitable to be topically applied for treating dermatoses, such as ichthyosis and psoriasis.

Abstract: A novel therapeutical use of L-carnitine, acyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed for the treatment of non-insulin-dependent patients with a view to enhancing their peripheral glucose utilization.

Abstract: This invention encompasses pharmaceutical compositions in the dietary supplement for treating or preventing fatty infiltration, the first stage of cirrhosis of the liver comprising and administering of not less than 1500 mg of betaine per kg of body weight per day. Dietary supplementation of betaine was shown to completely protect against liver fatty infiltration in rats exposed to prolonged ethanol intake as well as carbon tetrachloride. Hepatic levels of SAM were also elevated, which suggests the mechanism for the protection of the liver.

Abstract: A method of reducing the rate of mammalian hair growth includes topically applying a composition containing a sulfhydryl reactive compound to the skin.

Abstract: Antiinfective water-in-oil or oil-in-water emulsions comprising amphoteric surfactants of betaines and amine oxides, hydrophobic materials and emulsion aids.

Abstract: The present invention relates to a method of feeding female birds with a feed formulation which enhances the hatchability of the eggs laid, as evidenced by an increase in hatching percentage. Poultry diets of this invention include an amount of a carnitine, such as L-carnitine or a L-carnitine salt. The amount present in the diet is such that the hatchability of eggs laid by hens fed this diet is increased.

Abstract: The present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises treating the cells so as to render them resistant to an antitumor agent and contacting the resulting resistant cells under suitable conditions with an amount of a compound effective to selectively induce terminal differentiation of such cells. The compound has a structure:[R-A ]-B-[A.sub.1 -B.sub.1 -].sub.a [A.sub.2 -B.sub.2 -].sub.b [A.sub.3 -R.sub.1 ].The invention also concerns a method of treating a patient having a tumor characterized by proliferation of neoplastic which comprises administering to the patient an amount of an antitumor agent to render the cells resistant to the antitumor agent and subsequently administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.

Abstract: Acyl-Carnitine in pharmaceutical formulations provides therapeutic and preventive antiviral action against HSV, CMV, VZV, HIV and others.

Abstract: There is provided methods for inhibiting the activity of enveloped viruses, treatment of viral infections and method inactiviting sperm. There is provided articles for use in these methods.

Abstract: There is disclosed an oral composition including an organosilicon-type quaternary ammonium salt immobilized on a water-insoluble solid carrier. In particularly, an oral composition in an aqueous system according to the present invention includes an organosilicon-type quaternary ammonium salt immobilized on a water-insoluble solid carrier in combination with at least one surfactant selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymers and alkylolamides as a stabilizing agent; at least one thickening agent selected from the group consisting of nonionic thickening agents and cationic thickening agents; and optionally at least one alcohol selected from the group consisting of ethanol, propanol and isopropanol as a dispersing agent.

Abstract: The invention relates to a cosmetic composition comprising a mixture of(a) betaine,(b) ATP or an ATP generating system,(c) a magnesium salt, and(d) a potassium salt,in a cosmetically acceptable vehicle for topical administration and to a method for counteracting aging of the skin in a living human which utilizes the new composition.

Abstract: High viscosity fluids comprising amphoteric surfactants and Type A gelatin. These compositions can be used in shampoos, dentrifices and cosmetic and pharmaceutical preparations.

Abstract: Methods of treating reduced insulin-like growth factor levels and bone loss associated with aging which include administering L-carnitine and/or its precursors thereof are disclosed. Such administration results in increased serum insulin-like growth factor-1 and osteocalcin levels.

Abstract: This invention relates to a hair-restorer comprising, as an active ingredient, (a) an acyclic branched higher aliphatic hydrocarbon of 20 carbon atoms which may be substituted with hydroxyl group or acyloxy group, or (b) an acyclic branched carboxylic acid of 20 carbon atoms or its derivative and to a process for hair growth.

Abstract: The process of disinfecting at least one of food, human beings, animals and products to be brought in contact with same to combat microorganisms includes (a) providing a microbicidal composition comprised of an effective amount of at least one microbicide which is hydrolyzable at a pH-value ranging from about 6 to about 8.5 and is a long-chain alkyl ester compound having the general formula: ##STR1## wherein R.sup.I, R.sup.II and R.sup.III are hydrogen or lower alkyl groups having 1 to 4 carbon atoms, R.sup.IV is a long-chain alkyl group having 10 to 18 carbon atoms, R.sup.V is hydrogen or a group having the formula R.sup.VI N.sup.+ H.sub.3, wherein R.sup.VI is an alkylene group having 3 to 4 carbon atoms, A is a monovalent counter ion, and n is a number of cationic groups in the long chain-alkyl ester compound; and (b) exposing microorganisms to the microbicidal composition to inactivate the microorganisms.

Abstract: The use is described of acetyl L-carnitine and some of its pharmacologically acceptable salts in the therapeutic treatment of coma. 2000-4000 mg/day of acetyl L-carnitine or an equivalent quantity of one of its pharmacologically acceptable salts is administered, preferably by the parenteral route.

Abstract: Novel chemical compounds are provided which selectively inhibit the metabolism of dipeptidase (E.C.3.4.13.11) and therefore are useful in combination with antibacterial products. These chemical compounds are z-2-acylamino-3-monosubstituted propenoates.

Abstract: Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

Abstract: A prophylactic agent for controlling venereal diseases. As an active microbicidal component, the agent has an ammonium compound having hydrolyzable ester group.

Abstract: Tablets, capsules and other preparation forms for oral administration are produced which contain L-carnitine-L-tartrate. In comparison to preparations made with free L-carnitine, the invention preparations exhibit less hygroscopicity, longer stability and better capacity for being stored.

Abstract: A pharmaceutical composition for relieving symptoms of dysmenorrhea and/or premenstrual syndrome comprising a combination of ibuprofen and hydrochlorothiazide, and, optionally, an antihistamine.

Abstract: The use is described of acetyl L-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of cataract. The medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 10%-15% w/v of acetyl L-carnitine.

Abstract: Fish feed compositions supplemented with up to 0.5% L-carnitine, preferably between 0.01% to 0.3% L-carnitine, produce greater growth gains, decreased fat levels in tissues, and increased resistance to stress (ammonia toxicity) in fish, as compared to fish fed the same diet without supplemental carnitine.

Abstract: A method is described for preventing diet-induced Carnitine deficiency in domesticated dogs and cats. A daily prophylactic amount of gamma-butyrobetaine is administered to the pet either as a dietary supplement in an amount of 1.0 to 5.0 grams of gamma-butyrobetaine per day, or gamma-butyrobetaine is provided as an additional ingredient to a commercial pet food in an amount of 1.0 to 5.0 grams of gamma-butyrobetaine per kilogram pet food.

Abstract: Carnitine, aminocarnitine and cysteic acid serve as carriers to bring pharmaceutically active compounds to desired sites in the body, e.g. skeletal muscle or the heart. The pharmaceutically active compound can be a protease inhibitor, a cardioactive drug for combating arrythmia, etc. The linkage is chemical through one or more alcohol, carboxyl or amine groups using reagents such as glutaraldehyde, dicarboxylic acid anhydrides and acid halides and carbodiimides. Carnitine derivatives are also incorporated into liposomes which are then used as carriers of active pharmaceutical agents.

Abstract: The present invention relates to a new laevorotatory basic derivative of 9,10-ethanoanthracene, namely R-(-)-.alpha.-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol of the formula I ##STR1## and the acid addition salts thereof, to pharmaceutical compositions containing these new substances and to a method for treating dysphoric conditions, psychovegetative or psychosomatic disorders.

Abstract: Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

Abstract: L-carnitine is effective for the treatment of peripheral vascular diseases, such as intermittent claudication. Administration of L-carnitine to patients suffering from intermittent claudication results in a significant increase in the distance the patients can walk before experiencing claudication.